Breast Cancer Risk Not Raised by IBD Treatment
A multicenter retrospective study of 207 patients found no significant difference in incident cancer-free survival between treated and untreated groups.
Updated on Nov. 17, 2026 in Cancer

A multicenter retrospective study examined incident cancer rates in patients with inflammatory bowel disease and prior breast cancer, grouped by their IBD treatment. The study found no statistically significant increase in incident breast cancer linked to IBD treatment.
Why it matters
Patients with inflammatory bowel disease and a history of breast cancer often must weigh the risks of ongoing immunosuppressive therapy against the risk of cancer recurrence. The findings offer comparative data to inform those decisions, though the study is retrospective and its conclusions are limited accordingly.
Among 207 patients with IBD and prior breast cancer, 42 incident cancers were observed over a median follow-up of 71 months, with 34 of these being breast cancer recurrences. Incident cancer-free survival did not significantly differ between treated and control groups (P=0.4796), though adjusted incidence rates were 10.2 per 1,000 person-years untreated versus 28.9 per 1,000 person-years in exposed patients.
The details
Researchers analyzed consecutive patients with inflammatory bowel disease who had prior breast cancer, with a median disease duration of 13 years. First-line IBD treatments included conventional immunosuppressants (19.3%), anti-TNF therapy (19.8%), vedolizumab (7.2%) and ustekinumab (1.9%). In multivariable analysis, stage T4d disease, triple-negative tumors and follow-up under 71 months were associated with incident cancer.
Timeline
Median interval of 28 months between diagnosis and first-line IBD treatment.
Median follow-up period of 71 months for observing incident cancer.
Health Landscape
The study adds retrospective data to a clinical question that has grown more pressing as newer biologic and targeted IBD therapies have come into use in patients with a cancer history. Its comparison of treated and untreated groups fits a broader effort to define cancer risk across IBD treatment classes.
Patients with inflammatory bowel disease and a history of breast cancer may use these findings as one input when discussing treatment options with their clinicians. Any change to therapy should be made in consultation with a treating physician, since the study is retrospective and does not establish that a given treatment is safe or unsafe for an individual.
The takeaway
Treatment decisions for IBD patients with a cancer history involve trade-offs that are best reviewed case by case with a specialist. Retrospective findings like these can inform that conversation but do not replace individualized medical advice.
Further reading
Explore more research on cancer and how treatment choices affect long-term patient outcomes.
Source note: This article includes information reported by Derm Immuno Today.



